BIOMARIN PHARMACEUTICAL INC — Director's Dealing 2020

Jul 16, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK: 0001048477
Period of Report: 2020-04-30

Reporting Person: FUCHS HENRY J (President, Worldwide R&D)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-04-30	Common Stock	A	339	$62.586	Acquired	102995	Direct
2020-07-13	Common Stock	M	224	$67.81	Acquired	103219	Direct
2020-07-13	Common Stock	M	13810	$67.81	Acquired	117029	Direct
2020-07-13	Common Stock	M	8977	$63.10	Acquired	126006	Direct
2020-07-13	Common Stock	S	23011	$130.00	Disposed	102995	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-07-13	Stock Option (Right to buy Common Stock)	$67.810	M	224	Disposed	2023-05-14	Common Stock (224)	Direct
2020-07-13	Stock Option (Right to buy Common Stock)	$67.81	M	13810	Disposed	2023-05-14	Common Stock (13810)	Direct
2020-07-13	Stock Option (Right to buy Common Stock)	$63.10	M	8977	Disposed	2024-06-03	Common Stock (8977)	Direct

Footnotes

F1: Represents shares acquired by the reporting person on April 30, 2020, pursuant to the issuer's Employee Stock Purchase Plan.

F2: Trade made pursuant to a 10b5-1 plan executed on March 11, 2020.

F3: The price in column 4 is the weighted average price. The price actually received ranged from $130.00 to $130.025. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.

F4: Reflects the number of options outstanding after the transactions from this specific stock option grant.